Clinical trial · Interventional
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
A Phase II Pilot Study of Short Term (12 Week) Combination Chemotherapy (Stanford V) in Unfavorable Hodgkin's Disease
NCT00002715CI-TRIAL-00046584completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bleomycin sulfate | Biological | Bleomycin | ALIAS |
| Doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Mechlorethamine hydrochloride | Drug | Mechlorethamine | ALIAS |
| Prednisone | Drug | Prednisone | ALIAS |
| Stanford V regimen | Drug | — | UNRESOLVED |
| Vinblastine | Drug | Vinblastine | ALIAS |
| Vincristine sulfate | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Combination Chemotherapy (Stanford V)
- description
- A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule
- interventionNames
- Biological: Bleomycin sulfate
- Drug: Stanford V regimen
- Drug: Doxorubicin hydrochloride
- Drug: Etoposide
- Drug: Mechlorethamine hydrochloride
- Drug: Prednisone
- Drug: Vinblastine
- Drug: Vincristine sulfate
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed Hodgkin's lymphoma of any histology
* Unfavorable disease required
* Clinical stage IIIA, IIIB, IV, or IIB (non-bulky)
* Locally extensive stage I or II with either of the following:
* Mediastinal mass greater than 1/3 the maximum intrathoracic diameter
* Two or more extranodal sites
PATIENT CHARACTERISTICS:
Age:
* 18 to 60
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No prior malignancy except nonmelanomatous skin cancer
* No significant concurrent illness that precludes protocol participation
PRIOR CONCURRENT THERAPY:
* No prior treatment for Hodgkin's lymphoma
Biologic therapy
* Not specified
Chemotherapy
* Not specified
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Not specifiedReferences
Publications (2)
- RESULTHorning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Ann Oncol. 1996;7 Suppl 4:105-8. doi: 10.1093/annonc/7.suppl_4.s105. PMID 8836420
- RESULTBartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol. 1995 May;13(5):1080-8. doi: 10.1200/JCO.1995.13.5.1080. PMID 7537796